Jazz hits a high note with positive narcolepsy results

Jazz isn't tired of good news this month: following significant improvements in sleepiness and sleep apnea, the company trumpets positive narcolepsy data.

By Suzanne Elvidge • April 28, 2017

Bristol-Myers surprises with continued Opdivo growth

Despite setbacks in its clinical program, Bristol-Myers is still firmly committed to the lung cancer space and has laid out a broad program for its assets. 

By Lisa LaMotta • April 27, 2017

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

AstraZeneca still playing catch up in I/O

The British pharma is trying to hone its oncology strategy as it attempts to compete in what is becoming an increasingly crowded marketplace. 

By Suzanne Elvidge • April 27, 2017

Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

Immuno-oncology will be in the spotlight over the next few days as AstraZeneca, Bristol-Myers and Roche are set to present new details on their competing drugs.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • April 26, 2017

Medicines Co. charts ambitious late-stage tests for heart drug

The biotech hopes to quickly catch Amgen and the team of Sanofi and Regeneron, who are battling each other to secure an advantage in the PCSK9 market.

By Ned Pagliarulo • April 26, 2017

Cancer immunotherapy works, but how to find which patients will benefit?

Bristol-Myers Squibb has paired up with Foundation Medicine to explore new ways of identifying patients most likely to respond to immuno-oncology drugs like Opdivo.

By Ned Pagliarulo • April 25, 2017

Cel-Sci withdraws 2016 study protocol amendment

Could this be the light at the end of the tunnel for Cel-Sci's Multikine development?

By Suzanne Elvidge • April 25, 2017

EASL: Bristol-Myers' drug cuts liver fat in NASH

The mid-stage NASH drug showed potential in lowering both liver fat and fibrosis levels in overweight patients.

By Suzanne Elvidge • April 24, 2017

Lilly's abemaciclib hits mark in MONARCH 3

The highly anticipated CDK 4/6 inhibitor significantly improved progression-free survival, according to an interim analysis.

By Jacob Bell • April 24, 2017

EASL: Experimental drug slashes fatty liver markers in Phase 2

NGM Bio comes out of stealth mode to trumpet positive NASH data at the International Liver Congress. 

By Suzanne Elvidge • April 22, 2017

Prescribed Reading: What J&J says about the rest of pharma

J&J earnings predict a rough first quarter for big pharma, AbbVie has a bad week, and Lilly's surprise rejection is great news for Pfizer. 

By Lisa LaMotta • April 21, 2017

Hep C combo clears virus at 12 weeks

AbbVie and Enanta's hep C combo shows 99% response at 12 weeks. But in this crowded market, does it really matter?

By Suzanne Elvidge • April 21, 2017

Building a lab when constrained by space

Kendall Square has become a thriving hotspot for biotech and pharma, but real estate is both expensive and limited. Accelerated Commercialization Spaces offer companies a cost-friendly alternative. 

By Seth Taylor • April 20, 2017

Biopharma opening up to new ways of partnering on R&D

A report from Deloitte found the number of early-stage, science-focused collaborations to have increased rapidly over the past 10 years. 

By Ned Pagliarulo • April 20, 2017

AbbVie's PARP inhibitor fails two late-stage cancer trials

Veliparib did not meet primary endpoints in studies testing it as a treatment for lung and breast cancer.

By Jacob Bell • April 20, 2017

Novartis CAR-T candidate clinches breakthrough designation

It's the second such designation for the immunotherapy, which is in a dead heat with Kite Pharma's drug to be first to market.

By Jacob Bell • April 19, 2017

Positive results help Ultragenyx recover after prior failure

The ultra rare disease biotech announced positive topline results for its mid-stage drug partnered with Japan's Kyowa Hakko Kirin Co.

By Lisa LaMotta • April 19, 2017

Mateon announces positive topline data in ovarian cancer

Results from a combination study in recurrent ovarian cancer provided an early glimmer of hope in hard-to-treat patients.

By Suzanne Elvidge • April 19, 2017

Deja vu for Circassia with second allergy failure

The British biotech once again blames a high placebo effect for the failure of one of its allergy immunotherapies. 

By Lisa LaMotta • April 18, 2017

Allergan, Novartis ink NASH partnership

The deal will pair Allergan's drug cenicriviroc and Novartis' candidate LJN452 in a Phase 2b study of patients with the liver disease.

By Jacob Bell • April 18, 2017

OncoMed hit with another mid-stage failure

The company's shares plummeted further after another Phase 2 trial flopped.

By Jacob Bell • April 17, 2017

FDA digests Ritter's mid-stage microbiome data

The drug developer plans to milk the lactose intolerance market as it pushes its lead microbiome drug towards Phase 3.

By Suzanne Elvidge • April 13, 2017

Novan spikes on positive antifungal results

The topical drugmaker scored a win for its platform and is exploring options to move its therapy forward. 

By Lisa LaMotta • April 12, 2017

Neurocrine's Ingrezza secures FDA approval

The company's stock jumped more than 20% after the FDA approved the tardive dyskinesia drug — Neurocrine's first product cleared for market.

By Jacob Bell • April 12, 2017

Rebiotix gut bug knocks out C. diff. in PUNCH study

The microbiome treatment showed positive results in the Phase 2 trial testing the drug against the difficult-to-treat bacterial infection.

By Suzanne Elvidge • April 12, 2017